In this issue of Blood , Huber et al(1) present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).